Table 4.
Targeted therapy for NTM and/or Aspergillus in 364 patients. Drugs used in 189 patients who received anti-mycobacterial therapy and in 243 patients who received antifungal therapy.
| Drugs * | No. of Patients (%) |
|---|---|
| Targeted therapy (364) † | |
| NTM and Aspergillus therapy | 172 (47.3) |
| NTM therapy only | 85 (23.4) |
| Aspergillus therapy only | 6 (1.6) |
| No NTM or Aspergillus therapy | 101 (27.7) |
| Anti-mycobacterial therapy (189) | |
| Macrolide | 131 (69.3) |
| Quinolone | 107 (56.6) |
| Ethambutol | 101 (53.4) |
| Rifampin | 74 (39.2) |
| Amikacin | 20 (10.6) |
| Clofazimine | 6 (3.2) |
| Rifabutin | 5 (2.6) |
| Cefoxitin | 5 (2.6) |
| Tigecycline | 3 (1.6) |
| Linezolid | 2 (1.1) |
| Imipenem | 1 (0.5) |
| Pyrazinamide | 1 (0.5) |
| Streptomycin | 1 (0.5) |
| Cotrimoxazole | 1 (0.5) |
| Doxycycline | 1 (0.5) |
| Antifungal therapy (243) | |
| Itraconazole | 77 (31.7) |
| Amphotericin B | 47 (19.3) |
| Voriconazole | 24 (9.9) |
| Embolization | 19 (7.8) |
| Surgery | 14 (5.8) |
| Corticosteroids | 9 (3.7) |
| Caspofungin | 3 (1.2) |
| Posaconazole | 2 (0.8) |
| Isavuconazole | 2 (0.8) |
| Micafungin | 2 (0.8) |
* Values in brackets represent number of patients for whom data were available. † Number of patients in whom the targeted therapy for NTM and/or Aspergillus was performed.